Somnolence (17.3%), sedation (12.7%), constipation (6.7%), fatigue (5.3%); extrapyramidal symptoms < 5%; mean weight +0.9 kg vs +0.7 kg placebo; no clinically meaningful metabolic, prolactin, or cardiovascular effects; no serious treatment-related adverse events. This evidence concerns the gene PRL and Coma.